Holen Sie sich die Stockscreener-App
24.41
1.47%
-0.365
Handel nachbörslich:
24.41
0.005
+0.02%
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Presents a Compelling Value Investment Case - ChartMill
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - Investing.com
Zacks.com featured highlights include Air Lease, National Energy, Catalyst and JBT Marel - The Globe and Mail
Catalyst Pharmaceuticals at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Geopolitical Volatility Boosts Value Investing: 4 Low-PEG Picks - TradingView
Catalyst Pharmaceuticals: Exceptional Fundamentals Trading at 20-33% Discount - TradingView
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Intech Investment Management LLC Sells 46,656 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.0% After Raising Its 2026 Revenue Outlook And What’s Next - Sahm
(CPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 43.34% - Finviz
Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - The Manila Times
Catalyst Pharmaceuticals to Present Real-World Findings on Duchenne Muscular Dystrophy at 2026 MDA Conference - Quiver Quantitative
Catalyst Pharmaceuticals to Showcase Real‑World Findings in - GlobeNewswire
American Century Companies Inc. Purchases 770,198 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Record 2025 Results Highlight Rare Disease Growth Story - Sahm
Why Catalyst Pharmaceuticals (CPRX) Is Up 5.4% After Raising 2026 Revenue Guidance And Highlighting Rare Disease Portfolio - Yahoo Finance
Catalyst Pharmaceuticals to Showcase Real-World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference - Bitget
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Zacks Research Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-Buy - MarketBeat
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Strong Fundamental and Technical Setup - ChartMill
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Rafferty Asset Management LLC - MarketBeat
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Are Investors Undervaluing Catalyst Pharmaceuticals (CPRX) Right Now? - Yahoo Finance
Best Value Stocks to Buy for March 4th - Yahoo Finance Singapore
Catalyst Pharmaceuticals (CPRX) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CPRX: Citigroup Raises Price Target to $35.00, Maintains Buy Rat - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat
A Look At Catalyst Pharmaceuticals (CPRX) Valuation After Record 2025 Earnings And New 2026 Revenue Guidance - Sahm
Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat
Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey
Is Catalyst Pharmaceuticals (CPRX) Pricing Reflect Its Strong DCF Upside After Recent Flat Returns - Yahoo Finance
Why Catalyst Pharmaceuticals (CPRX) Is Down 5.0% After Issuing 2026 Guidance And Buyback PlanAnd What's Next - Sahm
CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - simplywall.st
Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus
Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India
Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - Nasdaq
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill
Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus
Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat
Catalyst's (CPRX) Q4 Revenue Surpasses Expectations, Eyes Future Growth - GuruFocus
Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks
Catalyst Pharmaceuticals (CPRX) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com
Record 2025 growth and 2026 outlook at Catalyst Pharmaceuticals (Nasdaq: CPRX) - Stock Titan
CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record $589 Million in 2025 Revenues, Projects Continued Growth for 2026 - Quiver Quantitative
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times
Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire
Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria
Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada
1.57%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):